Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau PET Imaging With 18F-AV-1451 in MAPT Mutation Carriers
NCT02676843Phase 2Completed
- Sponsor
- Columbia University
- Start
- Apr 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flortaucipir in Fronto-temporal lobar degeneration (FTLD), sponsored by Columbia University. Primary endpoint: Standardized Uptake Value Ratio at 12 months. Started Apr 2016; status: completed.
02
Drugs
flortaucipir
03
Conditions
Fronto-temporal lobar degeneration (FTLD)
Beyond the preview
Go deeper on NCT02676843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676843.